Search

803 Result(s)
Sort by

EASi-HF™ Phase III trial in patients with HFpEF

EASi-HF™ Phase III trial in patients with HFpEF

Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Living with type 2 diabetes

Living with type 2 diabetes

People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Introducing CIAS

Introducing CIAS

Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Living with GPP

Living with GPP

Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
Retinal Health Research

Retinal Health Research

Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
A Unique Bond: human and animal health

A Unique Bond: human and animal health

At Boehringer Ingelheim we are dedicated to animal and human health. We celebrate the truly unique bonds between people and their pets.
More health in vulnerable communities

More health in vulnerable communities

In an era of globalization and social connectivity, one-dimensional solutions often do not work anymore. Complex challenges need complex solutions.
Partnership with Precision Health Research, Singapore

Partnership with Precision Health Research, Singapore

Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.